​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 6-K

​

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

​

For the Month of April 2026

​

Commission File Number: 001-37710

​

​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​

​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

2

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​

​

Date: April 30, 2026

3

​

Exhibit 99.1

​

​

Total Voting Rights

​

Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 30, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) hereby notifies the market that as at April 30, 2026, the issued share capital of HUTCHMED consisted of 872,335,120 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

​

The above figure of 872,335,120 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED shares under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

​

For illustrative purposes only, the 872,335,120 ordinary shares would be equivalent to 872,335,120 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 174,467,024 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

​

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

​

CONTACTS

​

​